Antiviral agents: Selected publications

Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials
Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, Lischka P, Josephson F, Douglas CM, Umeh O, Miller V, Ljungman P; Resistant Definitions Working Group of the Cytomegalovirus Drug Development Forum.
Clin Infect Dis. 2018 Aug 22. doi: 10.1093/cid/ciy696

Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects
Kropeit D, von Richter O, Stobernack HP, Rübsamen-Schaeff H, Zimmermann H.
Clin Pharmacol Drug Dev. 2018 Jan;7(1):9-21. doi: 10.1002/cpdd.388. Epub 2017 Oct 2.

Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis
Quenelle DC, Birkmann A, Goldner T, Pfaff T, Zimmermann H, Bonsmann S, Collins DJ, Rice TL, Prichard MN.
Antiviral Res. 2018 Jan;149:1-6. doi: 10.1016/j.antiviral.2017.11.002. Epub 2017 Nov 4

AIC649 in Combination with Entecavir Leads to WHsAg Loss in the Woodchuck Animal Model of Chronic Hepatitis B
Paulsen D, Korolowicz K. E, Li B, Huang X, Suresh M, Yon C, Leng X, Kallakury B.V, Tucker R.D, Urban A, Pfaff T, Addy I, Menne S.
Poster AASLD 2017-10-24 

Drugs in development for herpes simplex and varicella zoster virus
Birkmann A, Zimmermann H.
Clin Pharmacol Ther. 2017 Feb 4. doi: 10.1002/cpt.647

Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial
Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Fife K, Selke S, Huang ML, Stobernack HP, Zimmermann H, Corey L, Birkmann A, Ruebsamen-Schaeff H.
JAMA. 2016 Dec 20;316(23):2495-2503. doi: 10.1001/jama.2016.18189. Erratum in: JAMA. 2017 Feb 14;317(6):648

Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of human cytomegalovirus clinical isolates to letermovir
Lischka P, Zhang D, Holder D, Zimmermann H.
Antiviral Res. 2016 Jun 23;132:204-209.

No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy
Edlefsen PT, Birkmann A, Huang ML, Magaret CA, Kee JJ, Diem K, Goldner T, Timmler B, Stoelben S, Ruebsamen-Schaeff H, Zimmermann H, Warren T, Wald A, Corey L.
Journal of Infectious Diseases J Infect Dis. (2016) April 7, 2016.

HSV antivirals – current and future treatment options
Birkmann A, Zimmermann H.
Curr Opin Virol. 2016 Feb 18;18:9-13.

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes
Schiffer J.T, Swan D.A, Magaret A, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H, Stoelben S, Timmler B, Zimmermann H, Melhem M.R, Van Wart S.A, Rubino C.M, Birkmann A.
Science Translational Medicine 03 Feb 2016:Vol. 8, Issue 324, pp. 324ra15.

AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B
Paulsen D, Weber O, Ruebsamen-Schaeff H, Tennant B, Menne S.
PLOS ONE | DOI:10.1371/journal.pone.0144383 December 14, 2015.

Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)
Lischka P, Michel D, Zimmermann H.
J Infect Dis. 2015 Jun 25. pii: jiv352.

The T cell-selective IL-2 mutant AIC284 mediates protection in a rat model of Multiple Sclerosis
Weishaupt A, Paulsen D, Werner S, Wolf N, Köllner G, Rübsamen-Schaeff H, Hünig T, Kerkau T, Beyersdorf N.
J Neuroimmunol. 2015 May 15;282:63-72. doi: 10.1016/j.jneuroim.2015.03.020. Epub 2015 Mar 27.

Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir
Goldner T, Zimmermann H, Lischka P.
Antiviral Res. 2015 Apr;116:48-50. doi: 10.1016/j.antiviral.2015.01.006. Epub 2015 Jan 28.

In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.
Wildum S, Zimmermann H, Lischka P.
Antimicrob Agents Chemother. 2015 Jun;59(6):3140-8. doi: 10.1128/AAC.00114-15. Epub 2015 Mar 16.

Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model
Biswas S, Sukla S, Goldner T, Field HJ, Kropeit D, Paulsen D, Welbers A, Ruebsamen-Schaeff H, Zimmermann H, Birkmann A.
Antimicrob Agents Chemother. 2014 Jul;58(7):3843-52. doi: 10.1128/AAC.02641-14. Epub 2014 Apr 21.

Helicase-primase inhibitor pritelivir for HSV-2 infection
Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L, Stoelben S, Huang ML, Selke S, Stobernack HP, Ruebsamen-Schaeff H, Birkmann A.
N Engl J Med. 2014 Jan 16;370(3):201-10. doi: 10.1056/NEJMoa1301150.

Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study
Stoelben S, Arns W, Renders L, Hummel J, Mühlfeld A, Stangl M, Fischereder M, Gwinner W, Suwelack B, Witzke O, Dürr M, Beelen DW, Michel D, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Budde K.
Transpl Int. 2014 Jan;27(1):77-86. doi: 10.1111/tri.12225.

Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation
Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhauser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kolling K, Stobernack HP, Lischka P, Zimmermann H, Rubsamen-Schaeff H, Champlin RE, Ehninger G.
N Engl.J Med 2014 370, 1781-1789.

Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure
Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P.
Antimicrob Agents Chemother. 2014;58(1):610-3. doi: 10.1128/AAC.01794-13. Epub 2013 Nov 4.

In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor
Wildum S, Paulsen D, Thede K, Ruebsamen-Schaeff H, Zimmermann H.
Antimicrob Agents Chemother. 2013 Nov;57(11):5320-9. doi: 10.1128/AAC.01377-13. Epub 2013 Aug 19.

Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir
Field HJ, Huang ML, Lay EM, Mickleburgh I, Zimmermann H, Birkmann A.
Antiviral Res. 2013 Nov;100(2):297-9. doi: 10.1016/j.antiviral.2013.08.024. Epub 2013 Sep 8.

Inactivated ORF virus shows antifibrotic activity and inhibits human hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in preclinical models
Paulsen D, Urban A, Knorr A, Hirth-Dietrich C, Siegling A, Volk HD, Mercer AA, Limmer A, Schumak B, Knolle P, Ruebsamen-Schaeff H, Weber O
PLoS ONE, 8, e74605. September 16, 2013 DOI: 10.1371/journal.pone.0074605.

Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors
May MM, Brohm D, Harrenga A, Marquardt T, Riedl B, Kreuter J, Zimmermann H, Ruebsamen-Schaeff H, Urban A.
Antiviral Res. 2012 Aug;95(2):182-91. doi: 10.1016/j.antiviral.2012.04.008. Epub 2012 May 10.

In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses
Marschall M, Stamminger T, Urban A, Wildum S, Ruebsamen-Schaeff H, Zimmermann H, Lischka P.
Antimicrob Agents Chemother. 2012 Feb;56(2):1135-7. doi: 10.1128/AAC.05908-11. Epub 2011 Nov 21.

Helicase-Primase Inhibitors as the Potential Next Generation of Highly Active Drugs against Herpes Simplex Viruses
Birkmann A, Hewlett G, Ruebsamen-Schaeff H, Zimmermann H.
Future Virology Vol. 6, No. 10, 2011;Pages 1199-1209 , DOI 10.2217/fvl.11.28 (doi:10.2217/fvl.11.28)

First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246
Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P, Zimmermann H, Rubsamen-Schaeff H.
Am J Transplant. 2011 May;11(5):1079-84. doi: 10.1111/j.1600-6143.2011.03530.x.

The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase
Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P.
J Virol. 2011 Oct;85(20):10884-93. doi: 10.1128/JVI.05265-11. Epub 2011 Jul 13.

Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor
Sukla S, Biswas S, Birkmann A, Lischka P, Zimmermann H, Field HJ.
J Antimicrob Chemother. 2010 Jul;65(7):1347-52. doi: 10.1093/jac/dkq135. Epub 2010 May 7.

Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant
Sukla S, Biswas S, Birkmann A, Lischka P, Ruebsamen-Schaeff H, Zimmermann H, Field HJ.
Antiviral Res. 2010 Jul;87(1):67-73. doi: 10.1016/j.antiviral.2010.04.008. Epub 2010 Apr 24.

In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246
Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, Ruebsamen-Schaeff H, Zimmermann H.
Antimicrob Agents Chemother. 2010 Mar;54(3):1290-7. doi: 10.1128/AAC.01596-09. Epub 2010 Jan 4.

Antiviral strategies to combat cytomegalovirus infections in transplant recipients.
Lischka P, Zimmermann H.
Curr Opin Pharmacol. 2008 Oct;8(5):541-8. doi: 10.1016/j.coph.2008.07.002. Epub 2008 Aug 25. Review.

Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity
Biswas S, Tiley LS, Zimmermann H, Birkmann A, Field HJ.
Antiviral Res. 2008 Oct;80(1):81-5. doi: 10.1016/j.antiviral.2008.04.005. Epub 2008 May 16.

Development and optimisation of a procedure for the production of Parapoxvirus ovis by large-scale microcarrier cell culture in a non-animal, non-human and non-plant-derived medium
Pohlscheidt M., Langer U, Minuth T, Bödeker B, Apeler H, Hörlein HD, Paulsen D, Rübsamen-Waigmann H, Henzler HJ, Reichl U.
Vaccine. 2008 Mar 17;26(12):1552-65. doi: 10.1016/j.vaccine.2008.01.032. Epub 2008 Feb 5.

Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection.
Kaufman HE, Varnell ED, Gebhardt BM, Thompson HW, Atwal E, Rübsamen-Waigmann H, Kleymann G.
J Ocul Pharmacol Ther. 2008 Feb;24(1):34-42. doi: 10.1089/jop.2007.0084.

Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection an latency in the guinea pig model of human genital herpes disease
Baumeister J1, Fischer R, Eckenberg P, Henninger K, Ruebsamen-Waigmann H, Kleymann G.
Antivir Chem Chemother. 2007;18(1):35-48.


If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact:

Katja Woestenhemke
(PR/Media Contact)

AiCuris GmbH & Co. KG
Friedrich-Ebert-Str. 475
42117 Wuppertal

Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: press(at)